|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
DK3421603T3
(da)
|
2009-05-02 |
2022-01-10 |
Genzyme Corp |
Genterapi for neurodegenerative forstyrrelser
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
JP5963743B2
(ja)
|
2010-04-23 |
2016-08-03 |
ユニバーシティ オブ マサチューセッツ |
Ｃｎｓターゲティングａａｖベクターおよびその使用方法
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
US9226976B2
(en)
|
2011-04-21 |
2016-01-05 |
University Of Massachusetts |
RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
MX349138B
(es)
|
2011-04-22 |
2017-07-13 |
Univ California |
Variones de virus adeno-asociados con capside variante y sus metodos de uso.
|
|
CN115120746A
(zh)
|
2013-05-15 |
2022-09-30 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
CA2907799A1
(en)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
EP3044318B1
(en)
|
2013-09-13 |
2019-05-01 |
California Institute of Technology |
Selective recovery
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
KR102288849B1
(ko)
|
2014-03-17 |
2021-08-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
|
US10280418B2
(en)
|
2014-03-18 |
2019-05-07 |
Univeristy Of Massachusetts |
RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
PT3137497T
(pt)
|
2014-05-02 |
2021-07-12 |
Genzyme Corp |
Vetores de aav para terapia genética na retina e snc
|
|
JP6634073B2
(ja)
*
|
2014-05-14 |
2020-01-22 |
エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. |
リソソーム蓄積症処置用のアデノ随伴ウイルスベクター
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
JP6842410B2
(ja)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
新規の高効率ライブラリーにより同定されるａａｖベクター
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
HK1247641A1
(zh)
|
2015-02-10 |
2018-09-28 |
Genzyme Corporation |
变体RNAi
|
|
LT3256594T
(lt)
|
2015-02-10 |
2022-02-10 |
Genzyme Corporation |
Patobulintas virusinių dalelių tiekimas į dryžuotąjį kūną ir smegenų žievę
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
JP7095994B2
(ja)
|
2015-03-02 |
2022-07-05 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
|
|
AU2016228751B2
(en)
*
|
2015-03-11 |
2022-01-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rp2 vectors for treating x-linked retinitis pigmentosa
|
|
CA2979065A1
(en)
|
2015-03-24 |
2016-09-29 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
DK3280432T3
(da)
|
2015-04-06 |
2021-04-26 |
Subdomain Llc |
Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
|
|
WO2016164642A1
(en)
|
2015-04-08 |
2016-10-13 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
WO2016172008A1
(en)
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
CA2996420A1
(en)
|
2015-09-28 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
DK3364997T5
(da)
|
2015-10-22 |
2024-09-30 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
|
EP3364996B1
(en)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
CA3007495C
(en)
*
|
2015-12-11 |
2023-04-11 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (aavs)
|
|
IL259964B
(en)
*
|
2015-12-15 |
2022-09-01 |
Genzyme Corp |
Adenovirus-associated vectors for the treatment of mucolipodosis type ii
|
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
|
US11060088B2
(en)
|
2016-02-12 |
2021-07-13 |
University Of Massachusetts |
Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
|
|
WO2017147477A1
(en)
*
|
2016-02-26 |
2017-08-31 |
University Of Florida Research Foundation, Inc. |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
WO2018009814A1
(en)
*
|
2016-07-08 |
2018-01-11 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving rdh12
|
|
WO2018011572A1
(en)
*
|
2016-07-12 |
2018-01-18 |
The University Of Manchester |
Gene therapy
|
|
CN116286986A
(zh)
|
2016-07-29 |
2023-06-23 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体和其使用方法
|
|
US20190262373A1
(en)
*
|
2016-08-16 |
2019-08-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
EP3500667A4
(en)
*
|
2016-08-18 |
2020-09-02 |
The Regents of the University of California |
GENOMIC ENGINEERING OF CRISPR-CAS THROUGH A MODULAR AAV DELIVERY SYSTEM
|
|
US20210283222A1
(en)
*
|
2016-08-19 |
2021-09-16 |
Calimmune, Inc. |
Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
|
|
JP7165410B2
(ja)
*
|
2016-08-19 |
2022-11-04 |
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド |
組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
MX392374B
(es)
|
2016-09-28 |
2025-03-24 |
Cohbar Inc |
Peptidos terapeuticos relacionados con mots-c.
|
|
US11078238B2
(en)
|
2016-09-29 |
2021-08-03 |
University Of Florida Research Foundation, Incorporated |
AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
EP3528785A4
(en)
|
2016-10-19 |
2020-12-02 |
Adverum Biotechnologies, Inc. |
MODIFIED AAV CASPIDS AND USES THEREOF
|
|
CA3046347A1
(en)
|
2016-12-07 |
2018-06-14 |
University Of Florida Research Foundation, Incorporated |
Il-1ra cdnas
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
WO2018156892A1
(en)
|
2017-02-23 |
2018-08-30 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
US10898585B2
(en)
|
2017-04-14 |
2021-01-26 |
Ptc Therapeutics .Inc. |
Gene therapy for AADC deficiency
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
MX2019013172A
(es)
*
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
AU2018265414B2
(en)
|
2017-05-10 |
2022-01-20 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses
|
|
CA3066077A1
(en)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
AU2018290954B2
(en)
*
|
2017-06-30 |
2023-07-13 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
AU2018311069A1
(en)
*
|
2017-08-03 |
2020-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
EP3676373A4
(en)
|
2017-08-28 |
2021-06-09 |
The Regents of The University of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
EP3684937A4
(en)
|
2017-09-22 |
2021-06-02 |
University of Massachusetts |
NEW DUAL SOD1 EXPRESSION VECTORS AND RELATED USES
|
|
US20200377887A1
(en)
*
|
2017-09-22 |
2020-12-03 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
EP3684932A1
(en)
|
2017-09-22 |
2020-07-29 |
Genzyme Corporation |
Variant rnai
|
|
AU2018350700B2
(en)
*
|
2017-10-16 |
2025-04-24 |
Vigeneron Gmbh |
AAV vectors
|
|
WO2019077159A1
(en)
*
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
IL274677B2
(en)
|
2017-11-14 |
2025-01-01 |
Arcellx Inc |
Therapies with multifunctional immune system cells
|
|
WO2019097454A1
(en)
*
|
2017-11-15 |
2019-05-23 |
Friedrich Miescher Institute For Biomedical Research |
Primate retinal pigment epithelium cell-specific promoter
|
|
MY204271A
(en)
*
|
2017-11-15 |
2024-08-20 |
Ucl Business Ltd |
Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
|
|
JP7522656B2
(ja)
|
2017-11-21 |
2024-07-25 |
クリスパー セラピューティクス アーゲー |
常染色体優性網膜色素変性の処置のための材料および方法
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
US20210017509A1
(en)
*
|
2018-03-23 |
2021-01-21 |
The Trustees Of Columbia University In The City Of New York |
Gene Editing for Autosomal Dominant Diseases
|
|
CA3094465A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
SG11202009451VA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Antibody-evading virus vectors
|
|
CN112272672A
(zh)
|
2018-04-03 |
2021-01-26 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
MX2020011386A
(es)
|
2018-04-27 |
2021-01-29 |
Spacecraft Seven Llc |
Terapia genica para la degeneracion del snc.
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3794126A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
EP3813845A4
(en)
|
2018-05-15 |
2022-10-26 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
EP3802836A4
(en)
*
|
2018-06-01 |
2022-10-19 |
University of Florida Research Foundation, Incorporated |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT RETINITIS PIGMENTOSA
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
AR114540A1
(es)
|
2018-08-03 |
2020-09-16 |
Genzyme Corp |
VARIANTE DE ARNi CONTRA a-SINUCLEÍNA
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
JP7624724B2
(ja)
|
2018-09-26 |
2025-01-31 |
カリフォルニア インスティテュート オブ テクノロジー |
標的遺伝子療法のためのアデノ随伴ウイルス組成物
|
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
CA3115782A1
(en)
*
|
2018-10-10 |
2020-04-16 |
Wisconsin Alumni Research Foundation |
Kir 7.1 gene therapy vectors and methods of using the same
|
|
EP3863662A1
(en)
*
|
2018-10-12 |
2021-08-18 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20230061069A1
(en)
*
|
2018-11-13 |
2023-03-02 |
Jayandharan Giridhara Rao |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
CN113227126A
(zh)
*
|
2018-11-26 |
2021-08-06 |
巴塞罗那自治大学 |
成纤维细胞生长因子21(fgf21)基因治疗
|
|
WO2020117715A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
PT3906066T
(pt)
*
|
2019-01-04 |
2024-02-06 |
Ultragenyx Pharmaceutical Inc |
Constructos de terapia génica para o tratamento da doença de wilson
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
WO2020154535A1
(en)
*
|
2019-01-23 |
2020-07-30 |
University Of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
EP3917944A1
(en)
|
2019-01-28 |
2021-12-08 |
Cohbar Inc. |
Therapeutic peptides
|
|
PT3850089T
(pt)
|
2019-02-04 |
2024-01-24 |
Freeline Therapeutics Ltd |
Polinucleótidos
|
|
JP7597380B2
(ja)
*
|
2019-03-04 |
2024-12-10 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
|
|
US12491264B2
(en)
|
2019-03-04 |
2025-12-09 |
Duke University |
Compositions and methods for the diagnosis and treatment of retinopathies
|
|
WO2020182722A1
(en)
*
|
2019-03-08 |
2020-09-17 |
Universite Paris-Saclay |
Improved therapeutic method for rare ocular diseases by gene replacement
|
|
SG11202110146VA
(en)
|
2019-03-21 |
2021-10-28 |
Stridebio Inc |
Recombinant adeno-associated virus vectors
|
|
MX2021012184A
(es)
*
|
2019-04-10 |
2022-01-24 |
Prevail Therapeutics Inc |
Terapias genicas para trastornos lisosomales.
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3969070A4
(en)
*
|
2019-05-13 |
2022-07-06 |
University of Pittsburgh - of the Commonwealth System of Higher Education |
POLYMER-BASED RETINA THERAPY IMPLANT AND METHOD OF MAKING AND USE THEREOF
|
|
AU2020278960A1
(en)
*
|
2019-05-17 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
|
KR20220035107A
(ko)
*
|
2019-06-10 |
2022-03-21 |
호몰로지 메디슨, 인크. |
Arsa 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
|
|
CA3144986A1
(en)
|
2019-06-27 |
2020-12-30 |
University Of Florida Research Foundation, Incorporated |
Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
RS66255B1
(sr)
*
|
2019-07-15 |
2024-12-31 |
Meiragtx Uk Ii Ltd |
Modifikovani proteini aav kapsida za lečenje artritične bolesti
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
EP4017873A4
(en)
*
|
2019-08-23 |
2023-12-20 |
Duke University |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH
|
|
US20220324921A1
(en)
*
|
2019-09-03 |
2022-10-13 |
University Of Cincinnati |
Methods and compositions for the treatment of als
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
JP2022551487A
(ja)
*
|
2019-10-10 |
2022-12-09 |
ソリッド・バイオサイエンシーズ・インコーポレーテッド |
改変されたａａｖカプシドおよびその使用
|
|
EP4045525A1
(en)
*
|
2019-10-17 |
2022-08-24 |
Stridebio, Inc. |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
|
AU2020369570A1
(en)
*
|
2019-10-23 |
2022-05-12 |
The Trustees Of The University Of Pennsylvania |
Compositions for DRG-specific reduction of transgene expression
|
|
WO2021092300A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
KR20220133941A
(ko)
*
|
2020-01-29 |
2022-10-05 |
젠자임 코포레이션 |
안과 유전자 치료를 위한 변형 아데노-관련 바이러스 캡시드 단백질 및 이의 사용 방법
|
|
US20230070477A1
(en)
*
|
2020-02-07 |
2023-03-09 |
The Trustees Of Culumbia University In The City Of New York |
Reprogramming the metabolome to delay onset or treat neurodegeneration
|
|
WO2021167919A1
(en)
*
|
2020-02-18 |
2021-08-26 |
The University Of North Carolina At Chapel Hill |
Aav capsid-promoter interactions and cell selective gene expression
|
|
WO2021173984A2
(en)
*
|
2020-02-28 |
2021-09-02 |
University Of Massachusetts |
Oligonucleotides for prnp modulation
|
|
IL296262A
(en)
*
|
2020-03-11 |
2022-11-01 |
Massachusetts Eye & Ear Infirmary |
Gene therapy for nmnat1-related retinal degeneration
|
|
KR20230113689A
(ko)
*
|
2020-03-31 |
2023-08-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 변이체 및 그의 용도
|
|
CA3174863A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Ana BUJ BELLO |
Vectors for the treatment of acid ceramidase deficiency
|
|
KR20230020394A
(ko)
|
2020-04-15 |
2023-02-10 |
보이저 테라퓨틱스, 인크. |
Tau 결합 화합물
|
|
IL298001A
(en)
|
2020-05-13 |
2023-01-01 |
Voyager Therapeutics Inc |
Redirecting tropism of adeno-associated virus capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
JP2023529503A
(ja)
*
|
2020-06-13 |
2023-07-10 |
オクロジェネクス インコーポレイテッド |
網膜症のためのａａｖ媒介性遺伝子導入
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
AU2021315876A1
(en)
|
2020-07-27 |
2023-02-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
BR112023001336A2
(pt)
|
2020-08-05 |
2023-02-14 |
Spacecraft Seven Llc |
Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)
|
|
AU2021320902A1
(en)
|
2020-08-07 |
2023-04-06 |
Spacecraft Seven, Llc |
Plakophilin-2 (PKP2) gene therapy using AAV vector
|
|
TW202227632A
(zh)
|
2020-08-19 |
2022-07-16 |
美商史崔德生物公司 |
用於治療雷特症候群之腺相關病毒載體
|
|
CN116249541A
(zh)
*
|
2020-09-04 |
2023-06-09 |
俄亥俄州创新基金会 |
具有增强的转导效率并在脑中广泛分布的重组腺相关病毒载体的新型工程化衣壳血清型
|
|
WO2022087238A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
KR20230148207A
(ko)
*
|
2021-02-22 |
2023-10-24 |
더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 |
안구 병태에 대한 바이러스 벡터-기반 유전자 요법
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
US20240218396A1
(en)
*
|
2021-04-26 |
2024-07-04 |
Grace Science, Llc |
Compositions and methods for treating ngyl1 deficiency
|
|
EP4399314A4
(en)
*
|
2021-09-06 |
2025-09-10 |
Huidagene Therapeutics Singapore Pte Ltd |
TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65
|
|
EP4433490A2
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
JP2024543918A
(ja)
|
2021-11-29 |
2024-11-26 |
上海瑞宏迪医薬有限公司 |
Ａａｄｃ、ｇｄｎｆポリヌクレオチド及びそのパーキンソン病を治療するための使用
|
|
CA3244192A1
(en)
|
2022-02-21 |
2025-01-22 |
Shanghai Regenelead Therapies Co Ltd |
VEGF-BINDING MOLECULE AND ITS PHARMACEUTICAL USE
|
|
EP4499154A1
(en)
*
|
2022-03-25 |
2025-02-05 |
REGENXBIO Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
EP4511482A1
(en)
*
|
2022-04-19 |
2025-02-26 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Recombinant aav vectors for treating neurodegenerative disorders
|
|
EP4514949A1
(en)
|
2022-04-25 |
2025-03-05 |
Hadasit Medical Research Services&Development Ltd. |
Methods and compositions for treating vision loss
|
|
EP4514402A2
(en)
*
|
2022-04-25 |
2025-03-05 |
Myrtelle Inc. |
Treatments of disorders of myelin
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
JP2025520967A
(ja)
|
2022-07-08 |
2025-07-03 |
オスペダーレ サン ラファエレ エス．アール．エル |
導入遺伝子カセット
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
WO2024015794A2
(en)
*
|
2022-07-12 |
2024-01-18 |
The Research Institute At Nationwide Children's Hospital |
Adeno-associated virus gene therapy products and methods
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218311A1
(fr)
|
2023-04-21 |
2024-10-24 |
Pulsesight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
WO2025128817A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
Artificial micrornas targeting tau
|
|
WO2025160452A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Methods for fus-based delivery of viral particles to the brain
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|